

**Kinser, Robin D.**

---

**From:** Patskan, George J.  
**Sent:** Wednesday, October 09, 2002 8:37 AM  
**To:** Kinser, Robin D.  
**Subject:** RE: biomarker selection

**Follow Up Flag:** Follow up  
**Due By:** Wednesday, October 23, 2002 5:00 PM  
**Flag Status:** Completed

The one addition for sure would be Willie to cover COPD. It is my understanding from Rick that Hans was going to appoint 1-3 people from CE to serve as clinical coordinators (??) for cancer, CVD and COPD to interface with the 3 disease coordinators; those folks could be useful as well if this sub-coordinator role is going to happen.

Using CO Hb as an example of a biomarker of biologically effective dose, I would put biomarkers of biologically effective dose under the broad umbrella of exposure not effect.

-----Original Message-----

**From:** Kinser, Robin D.  
**Sent:** Wednesday, October 09, 2002 12:24 AM  
**To:** Patskan, George J.  
**Cc:** Kinser, Robin D.  
**Subject:** RE: biomarker selection

You ask an interesting question. What I've been thinking about the most lately are probably best characterized as biomarkers of biologically effective dose, which may be a subclass of exposure, but may not be. Whom would you suggest needs to be added (or dropped??) if we were to also evaluate biomarkers of potential harm?

P.S. Thanks for such a prompt answer. I really am on vacation as soon as I send my itinerary email out, so don't expect to hear from me until I'm 50 years old and have finally seen Bruce Springsteen....

-----Original Message-----

**From:** Patskan, George J.  
**Sent:** Tuesday, October 08, 2002 2:13 PM  
**To:** Kinser, Robin D.  
**Subject:** RE: biomarker selection

Yes

Please let me know when this begins and what biomarkers will be next up for discussion. Based on the suggested members this appears to be only biomarkers of exposure; is that correct?

-----Original Message-----

**From:** Kinser, Robin D.  
**Sent:** Monday, October 07, 2002 7:16 PM  
**To:** Rustemeier, Klaus; remote Holt, Klaus von; Schepers, Georg; Feng, Shixia; Tricker, Anthony; Patskan, George J.  
**Cc:** Kinser, Robin D.; Roethig, Hans; Solana, Rick P.; Dempsey, Ruth; remote Reininghaus, Wolf; Haussmann, Hans-Juergen  
**Subject:** biomarker selection

Dear Colleagues--

I'm sure you recall that a group collaborated in the selection of biomarkers of exposure for the Total Exposure Study. As our work in Clinical Evaluation continues, we are asked to evaluate new products for which the initial biomarker selections may not be the most appropriate. The development of analytical techniques also has continued, and some biomarkers which were desirable for study but were not readily analyzable have been the subject of method development efforts and may now be quantified. With these facts in mind, I have spoken to Hans Roethig about setting up an internal panel for the review and acceptance (or rejection) of new biomarkers. The membership I propose for this panel is Shixia Feng, Klaus von Holt, Robin Kinser, George Patskan, Klaus Rustemeier, Georg Schepers, and Tony Tricker.

We would conduct our work via teleconferences as much as possible. I suspect the literature we would all be reviewing is cigarette smoke related literature that we each are reading anyway. Therefore, I don't think the work of this panel would interfere significantly with the current work commitments.

Please let me know of your availability to participate on this panel. I anticipate an inaugural conference call by the end of October.

I'm hoping you will all say "yes" to this request, and I will thank you in advance for your interest.

Best regards,  
Robin

Robin Kinser  
804-274-5905  
Robin.D.Kinser@pmusa.com